Kinetics of SARS-CoV-2 Viral Load in Hospitalized Patients
-
Published:2024-05-20
Issue:5
Volume:13
Page:429
-
ISSN:2076-0817
-
Container-title:Pathogens
-
language:en
-
Short-container-title:Pathogens
Author:
Panico Alessandra1ORCID, Bagordo Francesco2ORCID, Nolasco Emanuela3, Grassi Tiziana1ORCID, Bianco Annagrazia3, Indino Floriano3, Taurino Federica3, De Donno Antonella1ORCID, Lobreglio Giambattista3
Affiliation:
1. Department of Experimental Medicine, University of Salento, 73100 Lecce, Italy 2. Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, 70121 Bari, Italy 3. Clinical Pathology and Microbiology Unit, Vito Fazzi General Hospital, 73100 Lecce, Italy
Abstract
The rapid and accurate detection of infectious people is crucial in controlling outbreaks. The aim of this study was to evaluate the kinetics of the viral load expressed as Ct in COVID-19 hospitalized patients. Nasopharyngeal swab specimens were collected for RT-PCR testing. Forty-one subjects were recruited, of which 48.8% developed severe symptoms and 51.2% showed milder symptoms. The distribution of Ct values measured from the symptom onset showed that the kinetics of the viral load decreased with increasing time. A Ct of 25 (high viral load) was reached after a mean of 9.9 ± 4.8 days from the symptom onset, without a significant difference between patients with severe (10.9 ± 5.7 days) and milder (9.0 ± 3.9 days) symptoms. In 65.8% of cases, a high viral load was maintained for more than 7 days from the symptom onset, especially in patients with severe symptoms (70.6%). A Ct of 30 (moderate viral load) and of 38 (low viral load) were reached after a mean of 16.1 ± 8.1 and 28.5 ± 22.4 days from the symptom onset, respectively, with a significant difference between patients with severe (Ct = 30:17.9 ± 9.8 days; Ct = 38:34.6 ± 29.6 days) and milder (Ct = 30:14.3 ± 5.8 days; Ct = 38:22.7 ± 9.9 days) symptoms. These results provide an understanding of the viral kinetics of SARS-CoV-2 and have implications for pandemic control strategies and practices.
Reference40 articles.
1. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2;Muralidar;Biochimie,2020 2. Zizza, A., Sedile, R., Bagordo, F., Panico, A., Guido, M., Grassi, T., Banchelli, F., and Grima, P. (2023). Factors Associated with Pneumonia in Patients Hospitalized with COVID-19 and the Role of Vaccination. Vaccines, 11. 3. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data;Haas;Lancet,2021 4. Panico, A., Lobreglio, G., Bagordo, F., Zizza, A., De Donno, A., Rosato, C., Lazzari, R., Chicone, M., Indino, F., and Recchia, V. (2022). Antibody Response in Healthcare Workers before and after the Third Dose of Anti-SARS-CoV-2 Vaccine: A Pilot Study. Vaccines, 10. 5. Grassi, T., Lobreglio, G., Panico, A., Rosato, C., Zizza, A., Lazzari, R., Chicone, M., Indino, F., and Bagordo, F. (2022). Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine. Vaccines, 10.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|